000298212 001__ 298212
000298212 005__ 20250202015001.0
000298212 0247_ $$2doi$$a10.3389/fonc.2024.1484319
000298212 0247_ $$2pmid$$apmid:39850816
000298212 0247_ $$2pmc$$apmc:PMC11754403
000298212 0247_ $$2altmetric$$aaltmetric:172937515
000298212 037__ $$aDKFZ-2025-00219
000298212 041__ $$aEnglish
000298212 082__ $$a610
000298212 1001_ $$aHoffmann, Markus$$b0
000298212 245__ $$aMechanistic insights into HPV-positivity in non-smokers and HPV-negativity in smokers with head and neck cancer.
000298212 260__ $$aLausanne$$bFrontiers Media$$c2025
000298212 3367_ $$2DRIVER$$aarticle
000298212 3367_ $$2DataCite$$aOutput Types/Journal article
000298212 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737983133_9464
000298212 3367_ $$2BibTeX$$aARTICLE
000298212 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298212 3367_ $$00$$2EndNote$$aJournal Article
000298212 520__ $$aSeveral aspects of the involvement of HPV in the pathogenesis of HPV-associated diseases remain poorly understood including mechanistic aspects of infection and the question of why the majority of HPV-positive HNSCC-patients are non-smokers, whereas HPV-negatives are smokers. Our previous research, based on 1,100 patient samples, hypothesized an explanation for this phenomenon: Smoking induces upregulation of a mucosal protective protein (SLPI), which competes with HPV for binding to Annexin A2 (AnxA2), pivotal for HPV cell entry. Here we investigate the mechanistic aspects of our hypothesis using transfection assays.HaCaT and HeLa cell lines were used to investigate the effects of shRNA transfection and nicotine exposure on HPV16-PsV-uptake. Cells were treated with Lipofectamine™ RNAiMAX for 48 or 72 hours with specific shRNA-concentrations, while nicotine was added to the cell medium at the indicated concentrations. Protein isolation, SLPI- and AnxA2-quantification, LDH cytotoxicity assessment, HPV16-PsV-uptake measurement, mRNA-isolation, cDNA-synthesis and RT-qPCR were performed.In vitro transfection experiments with HPV16 pseudovirions (PsVs) showed that PsVs entered cells significantly better when SLPI was downregulated and significantly less when AnxA2 was downregulated. Nicotine exposure increased SLPI levels and reduced PsV uptake.The overexpression of SLPI caused by tobacco-smoking can hinder HPV cell entry by binding to AnxA2 and thus prevent successful HPV infection. Conversely, non-smokers have lower SLPI-levels, associated with an excess of unbound AnxA2, favoring HPV cell-entry. These findings support our hypothesis, suggesting a paradigm shift in understanding virus-related pathogenesis, particularly in the head and neck region, and the nature of HPV infection.
000298212 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000298212 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298212 650_7 $$2Other$$aAnnexin A2
000298212 650_7 $$2Other$$aHNSCC
000298212 650_7 $$2Other$$aHPV
000298212 650_7 $$2Other$$aSLPI
000298212 650_7 $$2Other$$asmoking
000298212 650_7 $$2Other$$aviral cell entry
000298212 650_7 $$2Other$$avirus infection
000298212 7001_ $$aHille, Susanne$$b1
000298212 7001_ $$aFazel, Asita$$b2
000298212 7001_ $$aLaudien, Martin$$b3
000298212 7001_ $$aWiegand, Susanne$$b4
000298212 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b5$$udkfz
000298212 7001_ $$aMüller, Oliver J$$b6
000298212 7001_ $$aQuabius, Elgar Susanne$$b7
000298212 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2024.1484319$$gVol. 14, p. 1484319$$p1484319$$tFrontiers in oncology$$v14$$x2234-943X$$y2025
000298212 909CO $$ooai:inrepo02.dkfz.de:298212$$pVDB
000298212 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000298212 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000298212 9141_ $$y2025
000298212 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2022$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:01:20Z
000298212 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:01:20Z
000298212 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:01:20Z
000298212 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:01:20Z
000298212 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000298212 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000298212 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000298212 980__ $$ajournal
000298212 980__ $$aVDB
000298212 980__ $$aI:(DE-He78)D335-20160331
000298212 980__ $$aUNRESTRICTED